Woorilife & Health, a South Korean OTC drug maker, failed to test high-risk ingredients for DEG/EG and lacked quality-unit oversight.
What happened
FDA reviewed records Woorilife & Health submitted after FDA's February 8, 2023, and July 12, 2023, requests under section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act; this was a records review, not an inspection. FDA found the firm did not test each shipment of each lot of high-risk components, including glycerin, propylene glycol, and sorbitol solution, to verify identity and screen for diethylene glycol (DEG) or ethylene glycol (EG). FDA also found the quality unit did not effectively exercise its authority to approve or reject components.
What FDA found
The firm did not perform at least one identity test on each incoming lot of high-risk components, including glycerin, propylene glycol, and sorbitol solution, using the USP test that detects diethylene glycol and ethylene glycol.
21 CFR 211.84(d)(1)The quality unit did not adequately exercise its responsibility and authority to approve or reject components in the materials system.
21 CFR 211.22(a)
What FDA wants
FDA asks the firm to respond in writing within 30 working days with a plan to correct the violations, including DEG/EG test results for retained high-risk component lots or implicated finished batches, a risk assessment for in-date products, customer notifications and recalls for contaminated lots, and improved component testing and quality-unit oversight. FDA also recommends a qualified CGMP consultant if the firm intends to resume making drugs for the U.S. market.
Who should pay attention
- brands that buy OTC drugs or toothpaste from this contract manufacturer
- drug makers using glycerin, propylene glycol, or sorbitol from high-risk suppliers
- companies that rely on supplier certificates of analysis for incoming ingredient testing
This is a summary. Read the original letter on fda.gov.